CATSCI LTD

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -2.8%

  £11,040,857 → £10,730,139

• Cash

  -58.3%

  £7,725,807 → £3,224,207

• Net assets

  -44.9%

  £1,441,830 → £794,900

  lowest in 4 filed years

• Employees

  -29.9%

  107 → 75

• Operating profit

  -22.6%

  -£111,982 → -£137,329

• Profit before tax

  -76%

  -£386,415 → -£680,012

• Wages

  -26.9%

  £4,544,633 → £3,319,980

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Grant Thornton UK LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”

Significant events

• “Like many in the industry CatSci Ltd experienced a decline in demand, particularly in H1 2024, due to the "Biotech Winter." This period of reduced investment in biotech companies was driven by rising interest rates, economic uncertainty, and investor caution.”
• “As the year progressed, demand rebounded, with Q4 delivering record revenue and profitability. This momentum has continued into 2025, and we anticipate accelerated growth in the coming year.”
• “In February 2024, both the EMI and unapproved schemes were modified by reducing the exercise price of the options from £4.73 to £0.01 per share. This resulted in an increase of the fair value of the options of £0.90 per share. This has resulted in an additional charge to profit and loss of £6,167 for 2024.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

7

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.